Research highlighted a set of actionable weaknesses created by loss of KMT2C and KMT2D, epigenetic regulators involved in tumor differentiation and fate control. The report ties the findings to the COMPASS complex and emphasizes how epigenetic disruption can expose “targetable” vulnerabilities in cancer. For oncology drug developers, the work adds another mechanism-linked rationale for exploring combination strategies and biomarker-driven patient selection centered on KMT2C/D status.